Literature DB >> 34269738

Anesthetic management during transsphenoidal pituitary surgery.

Kamilla Esfahani1, Lauren K Dunn.   

Abstract

PURPOSE OF REVIEW: Pituitary adenoma resections comprise a large proportion of intracranial tumor surgeries. This patient population is medically and physiologically complex and requires careful perioperative planning and management on the part of the anesthesiologist. This review will summarize anesthetic considerations for pre, intra, and postoperative management of patients undergoing transsphenoidal pituitary surgery. RECENT
FINDINGS: An endoscopic approach is favored for patients undergoing transsphenoidal pituitary surgery. Hemodynamic monitoring is important to maintain cerebral perfusion and avoid risk of bleeding; however, 'controlled' hypotension may have adverse effects. Multimodal analgesia is effective for the management of postoperative pain and may reduce the risk of postoperative complications, including respiratory depression and postoperative nausea and vomiting.
SUMMARY: Transsphenoidal pituitary surgery is a preferred approach for the surgical management of nonfunctioning pituitary macroadenomas with symptoms of mass effect and functioning adenomas that cannot be otherwise managed medically. Understanding tumor pathologies and systemic effects are essential for preoperative planning and providing safe anesthetic care during the perioperative period.
Copyright © Copyright © 2021 YEAR Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34269738     DOI: 10.1097/ACO.0000000000001035

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  1 in total

1.  Comparison of the effects of inhalational and total intravenous anesthesia on quality of recovery in patients undergoing endoscopic transsphenoidal pituitary surgery: a randomized controlled trial.

Authors:  Do-Hyeong Kim; Kyeong Tae Min; Eui Hyun Kim; Young Seo Choi; Seung Ho Choi
Journal:  Int J Med Sci       Date:  2022-06-13       Impact factor: 3.642

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.